Ironwood Pharmaceuticals (IRWD)
(Delayed Data from NSDQ)
$8.12 USD
-0.18 (-2.17%)
Updated May 3, 2024 04:00 PM ET
After-Market: $8.11 -0.01 (-0.12%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth D Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
IRWD 8.12 -0.18(-2.17%)
Will IRWD be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for IRWD based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IRWD
Earnings Preview: Ironwood Pharmaceuticals (IRWD) Q1 Earnings Expected to Decline
OPKO Health (OPK) And Entera Bio Announce Data for GLP-2
IRWD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Ironwood (IRWD) Q4 Earnings Miss, Revenues Beat Marginally
Ironwood Pharmaceuticals (IRWD) Reports Break-Even Earnings for Q4
Ironwood (IRWD) is on the Move, Here's Why the Trend Could be Sustainable
Other News for IRWD
Ironwood Pharmaceuticals: A Strong Buy on Solid Financials and Promising Drug Developments
Ironwood Pharmaceuticals to Present New Data on Once-Weekly Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF) at Digestive Disease Week® 2024
Stock Market Crash Warning: Don’t Get Caught Holding These 3 Biotech Stocks
Ironwood Pharmaceuticals to Host First Quarter 2024 Investor Update Call
Analysts Are Bullish on Top Healthcare Stocks: BioCryst (BCRX), Ironwood Pharma (IRWD)